Vivosphere as an oncology platform for colorectal cancer modeling and drug screening
Active Grant Awarded
- Award ID
- R44CA302245
- Recipient
-
Vivosphere LLC UEI QSAGDTU231N8
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $350,000
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 31% complete
- Place of performance
- Auburn, AL 36832, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded Vivosphere LLC a grant of $350,000 on Jul 27, 2026, under Cancer Detection and Diagnosis Research (CFDA 93.394). The award funds development of colorectal cancer-specific vivospheres, which are cell-laden hydrogel microspheres produced on the recipient's patented microfluidic encapsulation platform. The project will develop more pathophysiologically relevant vivosphere models, optimize key high-throughput screening assays, and generate patient-derived xenograft tumors in a mouse model as a benchmark for evaluating whether the vivosphere model recapitulates in vivo tumor biology.
The full $350,000 is obligated. The period of performance runs from the award date through an ultimate completion date of Jul 31, 2027, and work is performed in Auburn, Alabama (36832). The source does not identify any sub-recipients.
The program funds research to improve cancer screening, early detection, and diagnostic methods, and its description covers SBIR and STTR participation.
Description
- Abstract
- The development of three-dimensional (3D) disease models has paved the way for accelerated design, discovery, and validation of potential targets and drug compounds, thereby significantly reducing the time, cost, and labor involved in the drug discovery pipeline. 3D cancer models, such as self-aggregated spheroids, cancer organoids, and organ chips, have been established as more accurate and predictive than two-dimensional (2D) models for drug screening. However, current commercial 3D cancer models either lack control over tumor microenvironment (TME) or suffer from low consistency and throughput. This makes vivosphere a breakthrough product. Vivospheres are developed as a more physiologically relevant and high-throughput screening (HTS)-adaptable model. They are cell-laden hydrogel microspheres that are produced rapidly using our patented microfluidic encapsulation platform, making them a much higher throughput model than organ chips. The incorporation of hydrogel matrices in vivospheres can improve the consistency of tissues in size and shape, which is critical in obtaining high-quality results in HTS, and provide the ability to manipulate the TME, an important driver of appropriate cell phenotype and function. Compared to self-aggregation systems, vivosphere models support either aggregating or non-aggregating cells, and allow for CO-encapsulation of stromal cell component, which is lacking in organoid model. This project will develop more pathophysiologically relevant vivospheres for colorectal cancer disease modeling and optimize key assays used in HTS. Patient-derived xenograft tumors will be generated using a mouse model as a benchmark to evaluate the vivosphere model's ability to recapitulate in vivo tumor biology. The overarching goal of this project is to establish vivosphere as a complex in vitro platform that can reduce, refine, and ultimately replace animal use in preclinical cancer research. The outcome of this project will remove potential roadblocks to building disease-specific models for HTS.
Quick answers
Who received award R44CA302245?
R44CA302245 was awarded to Vivosphere LLC by National Cancer Institute (National Institutes of Health) on July 27, 2026.
How much is award R44CA302245 worth?
$350,000 has been obligated on R44CA302245.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award